Sanofi Pasteur’s New Influenza Vaccine Plant, US
U.S. FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Manufacturing Facility. Sanofi Pasteur committed to increasing its seasonal and pandemic influenza preparedness; New facility will increase production capacity in the U.S. – Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN) (NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has licensed its new influenza vaccine manufacturing facility.